Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review
The dilemma of whether to treat elderly patients with diffuse large B-cell lymphoma (DLBCL)
with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin …
with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin …
[HTML][HTML] Role of Radiotherapy in the Management of Elderly Patients With Lymphoma
Lymphoma in elderly patients has unique treatment challenges due to baseline co-
morbidities, nutrition status, impairment in functional capacities and fitness. While geriatric …
morbidities, nutrition status, impairment in functional capacities and fitness. While geriatric …
[HTML][HTML] ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with …
C Buske, M Hutchings, M Ladetto, V Goede, U Mey… - Annals of …, 2018 - Elsevier
Abstract The European Society for Medical Oncology (ESMO) consensus conference on
mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June …
mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June …
[HTML][HTML] Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: a Danish population-based cohort study
MB Juul, PH Jensen, H Engberg, S Wehberg… - European Journal of …, 2018 - Elsevier
Background Optimal treatment strategy for the oldest patients with diffuse large B-cell
lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical …
lymphoma (DLBCL) remains controversial, as this group often is precluded from clinical …
Management strategies and outcomes for very elderly patients with diffuse large B‐cell lymphoma
BACKGROUND The number of elderly patients with diffuse large B‐cell lymphoma (DLBCL)
in our aging society continues to rise, although the optimal management of very elderly …
in our aging society continues to rise, although the optimal management of very elderly …
Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England
L Hounsome, TA Eyre, R Ireland, A Hodson… - British journal of …, 2022 - nature.com
Background We wished to examine treatment and outcome patterns in older diffuse large B-
cell lymphoma (DLBCL) patients, with a focus on the effect of route-to-diagnosis to outcome …
cell lymphoma (DLBCL) patients, with a focus on the effect of route-to-diagnosis to outcome …
A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
KT Isaksen, MA Mastroianni, M Rinde… - Blood …, 2021 - ashpublications.org
Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet,
empirical knowledge about the treatment of older patients is limited because they are …
empirical knowledge about the treatment of older patients is limited because they are …
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B‐cell lymphoma: a Swedish lymphoma register study
T Wästerlid, M Mohammadi, KE Smedby… - Journal of internal …, 2019 - Wiley Online Library
Background Comorbidity impacts overall survival amongst patients with diffuse large B‐cell
lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics …
lymphoma (DLBCL). However, associations of comorbidity with lymphoma characteristics …
Impact of intended and relative dose intensity of R‐CHOP in a large, consecutive cohort of elderly diffuse large B‐cell lymphoma patients treated with curative intent …
TA Eyre, N Martinez‐Calle, C Hildyard… - Journal of internal …, 2019 - Wiley Online Library
Background The increasing incidence of diffuse large B‐cell lymphoma (DLBCL) in ageing
populations places a significant burden on healthcare systems. Co‐morbidity, frailty, and …
populations places a significant burden on healthcare systems. Co‐morbidity, frailty, and …
Front-line treatment of high grade B cell non-Hodgkin lymphoma
M Kesavan, TA Eyre, GP Collins - Current Hematologic Malignancy …, 2019 - Springer
Abstract Purpose of Review Rituximab-based chemoimmunotherapy has resulted in a
marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). We reflect …
marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). We reflect …